These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19802584)

  • 21. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.
    Durbin AP; Kirkpatrick BD; Pierce KK; Schmidt AC; Whitehead SS
    Vaccine; 2011 Sep; 29(42):7242-50. PubMed ID: 21781997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.
    Li XF; Deng YQ; Yang HQ; Zhao H; Jiang T; Yu XD; Li SH; Ye Q; Zhu SY; Wang HJ; Zhang Y; Ma J; Yu YX; Liu ZY; Li YH; Qin ED; Shi PY; Qin CF
    J Virol; 2013 Dec; 87(24):13694-705. PubMed ID: 24109223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.
    Ramírez R; Falcón R; Izquierdo A; García A; Alvarez M; Pérez AB; Soto Y; Muné M; da Silva EM; Ortega O; Mohana-Borges R; Guzmán MG
    Virus Genes; 2014 Oct; 49(2):185-95. PubMed ID: 24854144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a live attenuated dengue virus vaccine using reverse genetics.
    Blaney JE; Durbin AP; Murphy BR; Whitehead SS
    Viral Immunol; 2006; 19(1):10-32. PubMed ID: 16553547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of mutations in a candidate dengue 4 vaccine strain 341750 PDK20 and construction of a full-length cDNA clone of the PDK20 vaccine candidate.
    Kelly EP; Puri B; Sun W; Falgout B
    Vaccine; 2010 Apr; 28(17):3030-7. PubMed ID: 19874927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen.
    Alves RPDS; Pereira LR; Fabris DLN; Salvador FS; Santos RA; Zanotto PMA; Romano CM; Amorim JH; Ferreira LCS
    Clin Vaccine Immunol; 2016 Jun; 23(6):460-469. PubMed ID: 27030586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4.
    Hanley KA; Manlucu LR; Gilmore LE; Blaney JE; Hanson CT; Murphy BR; Whitehead SS
    Virology; 2003 Jul; 312(1):222-32. PubMed ID: 12890635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques.
    Züst R; Dong H; Li XF; Chang DC; Zhang B; Balakrishnan T; Toh YX; Jiang T; Li SH; Deng YQ; Ellis BR; Ellis EM; Poidinger M; Zolezzi F; Qin CF; Shi PY; Fink K
    PLoS Pathog; 2013; 9(8):e1003521. PubMed ID: 23935499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.
    Whitehead SS; Falgout B; Hanley KA; Blaney JE; Markoff L; Murphy BR
    J Virol; 2003 Jan; 77(2):1653-7. PubMed ID: 12502885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
    Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
    J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).
    Huang CY; Kinney RM; Livengood JA; Bolling B; Arguello JJ; Luy BE; Silengo SJ; Boroughs KL; Stovall JL; Kalanidhi AP; Brault AC; Osorio JE; Stinchcomb DT
    PLoS Negl Trop Dis; 2013; 7(5):e2243. PubMed ID: 23738026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.
    White LJ; Sariol CA; Mattocks MD; Wahala M P B W; Yingsiwaphat V; Collier ML; Whitley J; Mikkelsen R; Rodriguez IV; Martinez MI; de Silva A; Johnston RE
    J Virol; 2013 Mar; 87(6):3409-24. PubMed ID: 23302884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
    J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
    Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
    Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
    George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
    J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates.
    Thoresen D; Matsuda K; Urakami A; Ngwe Tun MM; Nomura T; Moi ML; Watanabe Y; Ishikawa M; Hau TTT; Yamamoto H; Suzaki Y; Ami Y; Smith JF; Matano T; Morita K; Akahata W
    J Virol; 2024 May; 98(5):e0023924. PubMed ID: 38647327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature.
    Pintado Silva J; Fenutria R; Bernal-Rubio D; Sanchez-Martin I; Hunziker A; Chebishev E; Veloz J; Kelly G; Kim-Schulze S; Whitehead S; Durbin A; Ramos I; Fernandez-Sesma A
    Exp Biol Med (Maywood); 2022 Dec; 247(24):2201-2212. PubMed ID: 36734144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.